Sapphire Therapeutics Report issue

For profit Phase 2
Founded: Bridgewater NJ United States (2000)
Status: Acquired by Helsinn (2009)

Organization Overview

First Clinical Trial
2005
NCT00219817
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

anamorelin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 2)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1